Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 3 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Amtixbio Co. Ltd. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 3 distinct examiners and 3 distinct art units, creating several separate examination channels within the same technology area.
CHEN, PO-CHIH is the busiest examiner, with 3 pending matters. That concentration makes this examiner’s issues a significant part of docket planning, while the other assignments require separate review for art-unit-specific practice and prior-art concerns.
Counsel should coordinate claim terminology and disclosure positions across the portfolio without assuming that one response will fit every record. Examiner-specific issue tracking can help identify which matters warrant immediate technical or amendment support.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHEN, PO-CHIH | 3 | 74.3% | +14.7% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.4% | +24.3% |
| KANE, TREVOR LOGAN | 1 | 68.8% | +53.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18918533 | COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION | CHEN, PO-CHIH | — |
| 18918511 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS | CHEN, PO-CHIH | — |
| 17761809 | USE OF GENE INVOLVED IN PASSAGE THROUGH BRAIN-BLOOD BARRIER AND SURVIVAL INSIDE BRAIN OF CAUSATIVE FUNGI OF MENINGOENCEPHALITIS | KANE, TREVOR LOGAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18918533 | COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION | CHEN, PO-CHIH | — |
| 18918511 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS | CHEN, PO-CHIH | — |
| 18918365 | FUNCTIONAL DERIVATIVE COMPOUNDS OF ALANINE AND PROLINE AMINO ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHEN, PO-CHIH | — |
| 18565735 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | WHITE, DAWANNA SHAR-DAY | — |
| 17761809 | USE OF GENE INVOLVED IN PASSAGE THROUGH BRAIN-BLOOD BARRIER AND SURVIVAL INSIDE BRAIN OF CAUSATIVE FUNGI OF MENINGOENCEPHALITIS | KANE, TREVOR LOGAN | — |
| Art Unit | Apps |
|---|---|
| 1621 | 3 |
| 1627 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18918533 | COMPOSITION AND METHODS FOR PREVENTING OR TREATING PHYTOPATHOGENIC FUNGAL INFECTION | CHEN, PO-CHIH | 1621 | §101§103Other | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18918511 | COMPOSITIONS AND METHODS FOR PREVENTING OR TREATING MYCOSIS | CHEN, PO-CHIH | 1621 | §103§112Other | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18918365 | FUNCTIONAL DERIVATIVE COMPOUNDS OF ALANINE AND PROLINE AMINO ACIDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | CHEN, PO-CHIH | 1621 | §103Other | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18565735 | BENZYLOXY-BENZYLAMINYL AMINO ACID DERIVATIVE FOR ADJUSTING TSLP/TSLPR SIGNAL TRANSMISSION | WHITE, DAWANNA SHAR-DAY | 1627 | §102DP | Non-Final OA | — | Pending | Sep 27, 2024 |
| 17761809 | USE OF GENE INVOLVED IN PASSAGE THROUGH BRAIN-BLOOD BARRIER AND SURVIVAL INSIDE BRAIN OF CAUSATIVE FUNGI OF MENINGOENCEPHALITIS | KANE, TREVOR LOGAN | 1657 | §102§112 | Non-Final OA | — | Pending | Apr 15, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAmtixbio Co. Ltd. has 5 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Po-Chih Chen has the most, with 3 of Amtixbio Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
